Edit
Tranzyme
http://www.tranzyme.com/?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tabLast activity: 23.04.2013
Total raised: $57.3M
Investors 1
| Date | Name | Website |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.02.2012 | - | $9.3M | - |
| 04.04.2011 | IPO | $48M | - |
Mentions in press and media 19
| Date | Title | Description |
| 23.04.2013 | Tranzyme Pharma and Ocera Therapeutics Announce Merger Agreement $20M Committed PIPE Financing to Close with Merger | |
| 01.02.2012 | GI treatments firm Tranzyme secures $9.3M in debt financing | Tranzyme, which completed an initial public stock offering last April, does not yet have any U.S. Food and Administration-approved drugs. The companies lead drug candidate is ulimorelin, a compound in phase 3 clinical trials for treatment o... |
| 08.11.2011 | BMY extends drug discovery collaboration with Tranzyme | The funding in the extension will be under the same terms and conditions as under the existing partnership. Tranzyme is also entitled to the same milestone payments set in the original agreement. Bristol-Myers Squibb and Tranzyme entered a ... |
| 11.10.2011 | Former Roche executive Abercrombie named to BioCryst board | Abercrombie, who has more than 30 years of experience in the pharmaceutical industry, takes the place of Stephen Biggar, who stepped down from BioCryst’s board effective Monday. Abercrombie was president and CEO of Roche’s North American op... |
| 21.09.2011 | Former Roche executive Abercrombie named to Tranzyme’s board | Tranzyme does not yet have any commercialized drugs. The company’s lead drug candidate is Ulimorelin, a compound being studied as a treatment for postoperative ileus, a condition in which the GI tract stops functioning normally following in... |
| 05.04.2011 | Stem cell therapy firm Aldagen withdraws plans for $80M IPO | Promoted Covid-19’s terrible toll on diabetes patients. What can be done? The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 04.04.2011 | Tranzyme Pharma’s public offering raises $48M but IPO has little bounce | Promoted Telemedicine’s potential to provide healthcare to the world’s most vulnerable Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| 01.04.2011 | Tranzyme IPO targeted for April 4; offering re-priced at $4 per share | The company likely had to lower its price to attract more buyers for stock in a company with no approved products and expensive late-stage clinical trials ahead. But Tranzyme sees a market opportunity and an unmet medical need for its lead ... |
| 09.03.2011 | NC’s next IPO? Tranzyme prices offering that could raise $65M | Promoted Clinical Care Capacity Planning Learn how to manage clinical care capacity more efficiently during uncertain times. SAP Promoted Telemedicine’s potential to provide healthcare to the world’s most vulnerable Teladoc Health Head of R... |
| 27.07.2010 | CED NAMES 25 NORTH CAROLINA COMPANIES TO WATCH | Research Triangle Park, NC - July 27, 2010 |
Show more